Showing results (1-10 of 58) with videos related to
Sort By:
Pageof 6
Science'S STKE : Signal Transduction Knowledge Environment|January 15, 2004
Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptorsPaul L PratherDrug Metabolism Reviews|September 26, 2013
The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense productsLisa K Brents, Paul L PratherThe Journal of Pharmacology and Experimental Therapeutics|August 17, 2002
Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptorsJing-Gen Liu, Paul L PratherThe Journal of Pharmacology and Experimental Therapeutics|January 25, 2005
Mechanism of bradykinin-induced Ca2+ mobilization in murine proximal tubule epithelial cellsManish M Tiwari, Paul L Prather, Philip R MayeuxFrontiers in Pharmacology|January 10, 2017
Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 SelectivityLirit N Franks, Benjamin M Ford, Paul L PratherThe Journal of Pharmacology and Experimental Therapeutics|April 11, 2009
The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonistsKathryn A Seely, Mark S Levi, Paul L PratherTrends in Pharmacological Sciences|February 7, 2017
Synthetic Pot: Not Your Grandfather's MarijuanaBenjamin M Ford, Sherrica Tai, William E Fantegrossi, et al.The Journal of Pharmacology and Experimental Therapeutics|April 19, 2002
Agonist, antagonist, and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective delta-opioid receptor ligandNancy A Martin, Michael B Ruckle, Stephanie L VanHoof, et al.Plos One|December 10, 2016
Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug DevelopmentBenjamin M Ford, Lirit N Franks, Anna Radominska-Pandya, et al.The Journal of Pharmacology and Experimental Therapeutics|August 6, 2005
Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptorsJennifer L Shoemaker, Michael B Ruckle, Philip R Mayeux, et al.Pageof 6